<DOC>
	<DOCNO>NCT02057965</DOCNO>
	<brief_summary>This study test hypothesis MSCs combination Everolimus facilitate Tacrolimus withdrawal , reduce fibrosis decrease incidence opportunistic infection compare standard tacrolimus dose .</brief_summary>
	<brief_title>Mesenchymal Stromal Cell Therapy Renal Recipients</brief_title>
	<detailed_description>Kidney transplantation improve survival quality life patient end-stage renal disease . Despite excellent short-term result , long-term survival transplant kidney improve accordingly last decade . Calcineurin inhibitor ( CNI ) cornerstone immunosuppressive therapy many year , due efficacy prevent acute rejection . However , CNI nephrotoxic side effect directly contribute renal dysfunction compromise long-term outcome . Consequently strong interest immunosuppressive ( IS ) regimens maintain efficacy prevention acute rejection , whilst reduce nephrotoxicity . In perspective combination mesenchymal stromal cell ( MSCs ) mTor inhibitor ( Everolimus ( Certican® ) ) might optimal strategy facilitate CNI ( tacrolimus ) withdrawal . MSCs IS property roles tissue repair everolimus proliferation signal inhibitor potent immunosuppressant effect . In experimental study combination mTor inhibitor MSCs show attenuate alloimmune response promote allograft tolerance . In total 70 de novo renal recipient , 18-75 year ages recruit transplant clinic LUMC . Thirty five patient include Certican/ MSC group 35 patient Certican/ standard dose tacrolimus group . Patients MSC treat group receive two dos autologous BM derive MSCs IV , 7 day apart , 6 7 week transplantation combination Certican® ( 1.5 mg b.i.d. ) . At time second MSC infusion tacrolimus withdraw 2 week ( 1 week dose tacrolimus halve , 2 week stop ) . Patients control group receive Certican® ( 1.5 mg b.i.d . ) standard dose tacrolimus ( level 6-8 ng/ml 6 week ) . Primary goal evaluate whether concentration-controlled Certican® MSCs compare Certican® standard tacrolimus renal transplant recipient reduce fibrosis quantitative Sirius Red scoring .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subject willing participate study , must able give informed consent consent must obtain prior study procedure . Recipients first kidney graft decease , livingunrelated nonHLA identical living relate donor &gt; 50 year age . Panel Reactive Antibodies ( PRA ) ≤ 10 % . Patients must able adhere study visit schedule protocol requirement . If female childbearing age , subject must nonpregnant , nonbreastfeeding , use adequate contraception . Double organ transplant recipient . Biopsy proven acute rejection ( accord Banff criterion ) first 6 week transplantation . Patients evidence active infection abscess ( exception uncomplicated urinary tract infection ) MSC infusion . Patients suffer hepatic failure . Patients suffer active autoimmune disease . Patients previous BM transplant . A psychiatric , addictive disorder compromise ability give truly informed consent participation study . Use investigational drug transplantation . Documented HIV infection , active hepatitis B , hepatitis C TB accord current transplantation inclusion criterion . Subjects currently active opportunistic infection time MSC infusion ( e.g. , herpes zoster [ shingle ] , cytomegalovirus ( CMV ) , Pneumocystis carinii ( PCP ) , aspergillosis , histoplasmosis , mycobacteria TB , BK ) transplantation . Malignancy ( include lymphoproliferative disease ) within past 25 year ( except squamous basal cell carcinoma skin treat evidence recurrence ) accord current transplantation inclusion criterion . Known recent substance abuse ( drug alcohol ) . Contraindications undergo BM biopsy . Patients recipient ABO incompatible transplant . Cold ischemia time &gt; 30 hr . Patients severe total hypercholesterolemia ( &gt; 7.5 mmol/L ) total hypertriglyceridemia ( &gt; 5.6 mmol/L ) ( patient lipid lower treatment control hyperlipidemia acceptable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mesenchymal Stromal Cells</keyword>
	<keyword>Allograft rejection</keyword>
	<keyword>Fibrosis</keyword>
</DOC>